Join the Thyroid Cancer group to help and get support from people like you.
Thyroid Cancer News
Related terms: Anaplastic thyroid cancer
GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
WEDNESDAY, April 24, 2024 – Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online...
Microwave Ablation Feasible for T1N0M0 Papillary Thyroid Carcinoma
FRIDAY, April 12, 2024 – For patients with multifocal papillary thyroid carcinoma (PTC), the rates of progression-free survival (PFS) do not differ between microwave ablation (MWA) and surgical...
Ozempic, Wegovy Won't Boost Thyroid Cancer Risk: Study
WEDNESDAY, April 10, 2024 – Wegovy, Ozempic and other drugs known as GLP-1 analogues have become wildly popular for controlling diabetes and helping folks lose weight. There were concerns that...
Microwave Treatment Could Be an Advance Against Thyroid Tumors
WEDNESDAY, April 3, 2024 – Microwaves could offer an alternative to surgery for some people with thyroid cancer, a new study suggests. Microwave ablation, which uses heat to destroy tumors, more...
Thyroid Cancer Prevalent Among Transgender Female Veterans
WEDNESDAY, Nov. 29, 2023 – There is a high prevalence of thyroid cancer among transgender female veterans, according to a study presented at the annual meeting of the American Thyroid Association,...
Exposure to PFAS Linked to Increased Rate of Thyroid Cancer
TUESDAY, Oct. 24, 2023 – Exposure to per- and polyfluoroalkyl substances (PFAS) is associated with an increased rate of thyroid cancer, according to a study published online Oct. 24 in eBioMedicine. ...
Birth Defects More Common in Babies Born to Moms Who've Had Cancer
TUESDAY, Oct. 10, 2023 – Teens and young adult women who survive cancer appear to have higher odds of delivering babies with birth defects, according to a new study. Knowing this, young women making...
Cediranib Shows Promise for Differentiated Thyroid Cancer
TUESDAY, Sept. 19, 2023 – The multitargeted tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor (VEGFR) pathway, cediranib, shows promise for differentiated thyroid...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 17, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx® (cabozantinib) for the treatment ...
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
South San Francisco, CA – December 1, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers
INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), ...
FDA Approves Tafinlar + Mekinist for the Treatment of BRAF-Positive Anaplastic Thyroid Cancer
May 4, 2018 – The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot...
FDA Approves Lenvima (lenvatinib) for Differentiated Thyroid Cancer
February 13, 2015 – The U.S. Food and Drug Administration today granted approval to Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease...
FDA Approves Nexavar to Treat Metastatic Differentiated Thyroid Cancer
November 22, 2013 – The U.S. Food and Drug Administration today expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer. Thyroid cancer is...
FDA Approves Cometriq (cabozantinib) to Treat Rare Type of Thyroid Cancer
November 29, 2012 – The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized). ...
Ask a question
To post your own question to this support group, sign in or create an account.